These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 1315160)

  • 21. Effects of three azole derivatives on the lipids of different strains of Cryptococcus neoformans.
    Franzot SP; Hamdan JS
    Mycoses; 1995; 38(5-6):183-9. PubMed ID: 8531929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azoles.
    Jesus FP; Lautert C; Zanette RA; Mahl DL; Azevedo MI; Machado ML; Dutra V; Botton SA; Alves SH; Santurio JM
    Vet Microbiol; 2011 Aug; 152(1-2):161-4. PubMed ID: 21658868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug susceptibility testing of Malassezia furfur strains to antifungal agents.
    Zissova LG; Kantarjiev TB; Kuzmanov AH
    Folia Med (Plovdiv); 2001; 43(3):10-2. PubMed ID: 11930825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo.
    Clemons KV; Homola ME; Stevens DA
    Antimicrob Agents Chemother; 1995 May; 39(5):1169-72. PubMed ID: 7625808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In-vitro and in-vivo activity of itraconazole].
    Van Cutsem J
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azole antifungals: 35 years of invasive fungal infection management.
    Allen D; Wilson D; Drew R; Perfect J
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):787-98. PubMed ID: 25843556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
    Grant SM; Clissold SP
    Drugs; 1989 Mar; 37(3):310-44. PubMed ID: 2540949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azole drug resistance in yeasts.
    Johnson EM; Warnock DW
    J Antimicrob Chemother; 1995 Nov; 36(5):751-5. PubMed ID: 8626255
    [No Abstract]   [Full Text] [Related]  

  • 31. Current and emerging azole antifungal agents.
    Sheehan DJ; Hitchcock CA; Sibley CM
    Clin Microbiol Rev; 1999 Jan; 12(1):40-79. PubMed ID: 9880474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Pinus sylvestris L. (Pinaceae), Origanum vulgare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae) essential oils and their main components to enhance itraconazole activity against azole susceptible/not-susceptible Cryptococcus neoformans strains.
    Scalas D; Mandras N; Roana J; Tardugno R; Cuffini AM; Ghisetti V; Benvenuti S; Tullio V
    BMC Complement Altern Med; 2018 May; 18(1):143. PubMed ID: 29724221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
    Back DJ; Tjia JF
    Br J Clin Pharmacol; 1991 Nov; 32(5):624-6. PubMed ID: 1659439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Itraconazole therapy for cryptococcal meningitis and cryptococcosis.
    Denning DW; Tucker RM; Hanson LH; Hamilton JR; Stevens DA
    Arch Intern Med; 1989 Oct; 149(10):2301-8. PubMed ID: 2552949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole.
    Ganer A; Arathoon E; Stevens DA
    Rev Infect Dis; 1987; 9 Suppl 1():S77-86. PubMed ID: 3027851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
    Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P
    Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of azoles for systemic antifungal therapy.
    Kauffman CA; Carver PL
    Adv Pharmacol; 1997; 39():143-89. PubMed ID: 9160115
    [No Abstract]   [Full Text] [Related]  

  • 39. Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa.
    Warrilow AG; Price CL; Parker JE; Rolley NJ; Smyrniotis CJ; Hughes DD; Thoss V; Nes WD; Kelly DE; Holman TR; Kelly SL
    Sci Rep; 2016 Jun; 6():27690. PubMed ID: 27291783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.
    Venkateswarlu K; Denning DW; Kelly SL
    J Med Vet Mycol; 1997; 35(1):19-25. PubMed ID: 9061581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.